Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis

Alexander J. Kovalic, Sanjaya Satapathy, Naga Chalasani

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently one of the leading forms of chronic liver disease, and its rising frequency worldwide has reached epidemic proportions. NAFLD, particularly its progressive variant NASH (non-alcoholic steatohepatitis), can lead to advanced fibrosis, cirrhosis, and HCC. The pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex, and as such myriad therapies are under investigation targeting different pathophysiological mechanisms. Incretin-based therapies, including GLP-1RAs and DPP-4 inhibitors and the inhibition of ASK1 pathway have provided two such novel mechanisms in the management of this disease, and will remain focus of this review.

Original languageEnglish (US)
Pages (from-to)97-106
Number of pages10
JournalHepatology International
Volume12
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Incretins
Fatty Liver
Hormones
Fibrosis
Disease Management
Liver Diseases
Chronic Disease
Therapeutics
Non-alcoholic Fatty Liver Disease

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis. / Kovalic, Alexander J.; Satapathy, Sanjaya; Chalasani, Naga.

In: Hepatology International, Vol. 12, No. 2, 01.03.2018, p. 97-106.

Research output: Contribution to journalReview article

@article{77fa1ee7dacd4991b398a30960efe18a,
title = "Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is currently one of the leading forms of chronic liver disease, and its rising frequency worldwide has reached epidemic proportions. NAFLD, particularly its progressive variant NASH (non-alcoholic steatohepatitis), can lead to advanced fibrosis, cirrhosis, and HCC. The pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex, and as such myriad therapies are under investigation targeting different pathophysiological mechanisms. Incretin-based therapies, including GLP-1RAs and DPP-4 inhibitors and the inhibition of ASK1 pathway have provided two such novel mechanisms in the management of this disease, and will remain focus of this review.",
author = "Kovalic, {Alexander J.} and Sanjaya Satapathy and Naga Chalasani",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s12072-018-9854-1",
language = "English (US)",
volume = "12",
pages = "97--106",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis

AU - Kovalic, Alexander J.

AU - Satapathy, Sanjaya

AU - Chalasani, Naga

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Non-alcoholic fatty liver disease (NAFLD) is currently one of the leading forms of chronic liver disease, and its rising frequency worldwide has reached epidemic proportions. NAFLD, particularly its progressive variant NASH (non-alcoholic steatohepatitis), can lead to advanced fibrosis, cirrhosis, and HCC. The pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex, and as such myriad therapies are under investigation targeting different pathophysiological mechanisms. Incretin-based therapies, including GLP-1RAs and DPP-4 inhibitors and the inhibition of ASK1 pathway have provided two such novel mechanisms in the management of this disease, and will remain focus of this review.

AB - Non-alcoholic fatty liver disease (NAFLD) is currently one of the leading forms of chronic liver disease, and its rising frequency worldwide has reached epidemic proportions. NAFLD, particularly its progressive variant NASH (non-alcoholic steatohepatitis), can lead to advanced fibrosis, cirrhosis, and HCC. The pathophysiologic mechanisms that contribute to the development and progression of NAFLD and NASH are complex, and as such myriad therapies are under investigation targeting different pathophysiological mechanisms. Incretin-based therapies, including GLP-1RAs and DPP-4 inhibitors and the inhibition of ASK1 pathway have provided two such novel mechanisms in the management of this disease, and will remain focus of this review.

UR - http://www.scopus.com/inward/record.url?scp=85044539635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044539635&partnerID=8YFLogxK

U2 - 10.1007/s12072-018-9854-1

DO - 10.1007/s12072-018-9854-1

M3 - Review article

VL - 12

SP - 97

EP - 106

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 2

ER -